BOSTON, Nov. 26 /PRNewswire/ -- Surface Logix, Inc. today announced
that Jim Mahoney, President and Chief Executive Officer, will present an
update of the company's drug development pipeline at the 19th Annual Piper
Jaffray Health Care Conference being held November 27-29, 2007 at The
Pierre Hotel in New York City. Mr. Mahoney's presentation will take place
on Wednesday, November 28, 2007 at 2:50 PM EST.
Surface Logix currently has two programs in human clinical trials with
a third program in the IND preparation stage. Mr. Mahoney will discuss the
latest results for SLx-2101 and SLx-4090. SLx-2101, a second-generation
PDE5 inhibitor designed to address cardiovascular indications, is currently
in two separate Phase 2a trials, one in hypertension and another in
Raynaud's syndrome. SLx-4090, a first-in-class enterocyte-specific MTP
inhibitor for the treatment of dyslipidemia and potentially other
indications, is also in Phase 2a.
About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) with superior
drug-like properties that are clearly differentiated from competitive
products. The company is advancing multiple internal programs focused
primarily on cardiovascular, metabolic, oncologic and fibrotic diseases.
For more information, please visit http://www.surfacelogix.com.
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Sarah Cavanaugh
MacDougall Biomedical Communications, Inc.
scavanaugh@macbiocom.com
508.647.0209
SOURCE Surface Logix, Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Leland Webster, Ph.D., M.B.A., Vice
President, Corporate Development of Surface Logix, Inc.,
+1-617-746-8520; Sarah Cavanaugh of MacDougall Biomedical
Communications, Inc. for Surface Logix, Inc.,
scavanaugh@macbiocom.com, +1-508-647-0209
|
